Myelodysplastic syndromes. Diagnosis and therapeutic strategies;Myelodysplastische syndrome: Aktueller stand der diagnostik und therapie

Medizinische Klinik

Volumn 97, Issue 11, 2002, Pages 666-676

  Aul, Carlo ^a   Giagounidis, Aristoteles ^a   Germing, Ulrich ^b   Ganser, Arnold ^c  

^a ST JOHANNES HOSPITAL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Myelodysplastic syndromes; Risk stratification; Therapeutic strategies

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMIFOSTINE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PENTOXIFYLLINE; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL EXAMINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; MYELODYSPLASTIC SYNDROME; PROGNOSIS; RECURRENCE RISK; REVIEW; SCORING SYSTEM; TREATMENT INDICATION;

ADULT; AGE FACTORS; BONE MARROW EXAMINATION; DISEASE-FREE SURVIVAL; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; REMISSION INDUCTION; RISK ASSESSMENT; RISK FACTORS; STEM CELL TRANSPLANTATION; TIME FACTORS;

EID: 0037112853     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-002-1210-4     Document Type: Review

References (49)

1. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemioiogical aspects of myelodysplastic syndromes. Br J Haematol 1993; 82:358-67.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAH, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
3. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting -Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
4. Heim S. Cytogenetic findings in primary and secondary MDS. Leuk Res 1992;16:43-6.
5. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International prognostic scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
6. Aul C, Gattermann N, Heyll A, Germing U. Derigs G, Schneider W. Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992:6:52-9.
7. Franchini M, Gandini G, De Gironcoli M, Vassanelli A., Borgna-Pignatti C, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 2000;95: 2776-9.
8. Greenberg P, Taylor K, Larson P, Koeffler P, Negrin RE. Phase III randomized multicenter trial of G-CSF vs. observation for MDS. Blood 1993;82:196.abstract.
9. Hellström-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Ost A, Greenberg P. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposal for a predictive model. Br J Haematol 1997;99:344-51.
10. Molldrem JJ, Caples M, Mavrou, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99:699-705.
11. Jonasova A, Neuwirtova R, Cermtak J, Vozobulova V, Mocikova K, Siskova, M, Hochova I. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998;100:304-9.
12. Aul C, Gattermann N. The role of low-dose chemotherapy in myelodysplastic syndromes. Leuk Res 1992;16:207-15.
13. Juneja HS, Jodhani M, Gardner FH, Trevarthen D, Schottstedt M. Low-dose ARA-C consistently induces hematologic responses in the clinical 5q-syndrome. Am J Hematol 1994;46:338-42.
14. Miller KB, Kyungman K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DP, Cassileth PA, O'Connell MJ. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase III intergroup study. Ann Hematol 1992;65:162-8.
15. Silverman LR, Demakos EP, Meterson B. A randomized trial of subcutaneous azacytidine (AZA C) in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B (CALGB). Proc Am Soc Clin Oncol 1998;17:14.abstract.
16. Wijermans PW, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A. Low-dose 5-aza-2′deoxycytidine, a DNA hypomethylating agent, for the treatment of high risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-62.
17. Omoto E, Deguchi S, Takaba S, Kojima K. Yano T, Karayama Y, Sunami K, Takeuchi M, Kimuara F, Harada M, Kimura I. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Leukemia 1996;10:609-14.
18. Denzlinger C, Benz D, Bowen D, Gelly K, Brugger W, Kanz L. Low-dose melphalan induces favourable responses in elderly patients with high risk myelodysplastic syndromes or secondary leukemia. Br J Haematol 2000;108:93-5.
19. Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahe B, Couteaux ME, Resegotti L, Voglova V, Foussard C, Pegourie B, Michaux JL, Deconinck E, Stoppa AM, Mafti G, Oscier D, Fenaux P, Groupe Français des Myélodysplasies & European CMML Group. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Blood 1996; 88:2480-7.
20. Michels SD, Saumur J, Arthur DC, Robison LL, Brunning RD. Refractory anemia with excess of blasts in transformation: Hematologic and clinical study of 52 patients. Cancer 1989;64:2340-6.
21. De Witte T, Muus P, de Pauw B, Haanen C. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 1990;66:831-7.
22. Estey EE, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-T) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther 1995;1:21-8.
23. De Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Seelleslag D, Zittoun R, Dardenne M, Solbu G, Zwierzins H, Muus P. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 1995;9:1805-11.
24. Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfield CD. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: A Cancer and Leukemia Group B study. J Clin Oncol 1996;14:2486-94.
25. Aul C, Runde V, Genning U, Burk M, Heyll A, Hildebrandt B, Willers R. Remission rates, survival and prognostic factors in 90 patients with advanced MDS treated with intensive chemotherapy. Ann Hematol 1995;70:Suppl 2:138.abstract.
26. Ganser A, Hell GT, Seipelt G, Hofmann W, Fischer JT, Langer W, Brockhaus W, Kolbe K, Ittel TH, Brack N, Fuhr HG, Knuth P, Höffken K, Bergmann L, Hoelzer D. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk acute mye-loid leukemia (AML). Ann Hematol 2000;79:30-5.
27. Beran M, Kantarjian H, O'Brien S, Koller C, AlBitar M, Arbuck S, Pierce S, Moore M, Abbruzzese JL, Andreeff M, Keating M, Estey E. Topotecan, a topoisomerase 1 inhibitor, is active in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. Blood 1996;88:2473-9.
28. Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB, Johnson SA, Carey P, Mackie MJ, Ganly PS, Turner GE, Deane M, Schey S, Brookes J, Tollerfield SM, Wilson MP. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 2001;112:127-37.
29. Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A, Mahé B, Milpied N, Janvier M, Guerci A, Rochant H, Cordonnier C, Dreyfus F, Buzyn A, Hoang-Ngoc L, Stoppa AM, Gratecos N, Sadoun A, Stamatoulas A, Tilly H, Brice P, Maloisel F, Lioure B, Desablens B, Pignon B, Abgrall JP, Leporrier M, Dupriez B, Guyotat D, Lepelley P, Fenaux P. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing the P glycoprotein: Results of a randomized study. Br J Haematol 1998;102:1015-24.
30. Sutton L, Chastang C, Ribaud P, Jouet JP. Kuentz M, Attal M, Reiffers J, Tigaud JM, Rio B, Dauriac C, Legros M, Dreyfus F, Lioure B, Troussard X, Milpied M, Witz F, Oriol P, Cahn JY, Michallet M, Gluckman E, Ifrah N, Pico JL, Vilmer E, Leblond E, for the Société Française de Greffe de Moelle. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long-term study of 71 patients. Blood 1996;88:358-65.
31. Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, Niederwieser D, Labopin M, Walter-Noel MP, Bacigalupo A, Jacobsen N, Ljungman P, Carreras E, Kolb HJ, Aul C, Apperley J, on behalf of the Chronic Leukemia Working Parry of the European Group for Blood and Marrow Transplantation. Bone marrow transplantation from HLA-identical sibling as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome. Bone Marrow Transplant 1998;21:255-61.
32. Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG, Forrest DL, Toze CL, Sutherland HJ, Hogge DE, Naiman SC, Le A, Brockington DA, Barnett MJ. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998;92:1910-7.
33. Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT, Anasetti C, Fefer A, Storb R, Appelbaum FR. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000;95:1188-94.
34. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score. Leukemia 1998;12:Suppl 1:25-9.
35. De Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, Ruutu T, Ljungman P, Gratwohl A, Runde V, Niederwieser D, van Biezen A, Devergie A, Cornelissen J, Jouet JP, Arnold R, Apperley J. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110:620-30.
36. De Witte T, van Biezen A, Hermans J, Labopin M, Runde V, Or R, Meloni G, Brunet-Mauri S, Carella A, Apperley J, Gratwohl A, Laporte JP, for the Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood 1997;90:3853-9.
37. Visani G, Tosi P, Manfroi S, Ottaviani E, Finelli C, Cenacchi A, Bendandi M, Tura S. All-trans retinoic acid in the treatment of myelodysplastic syndromes. Leuk Lymphoma 1995;19:277-80.
38. Cambier N, Baruchel A, Schlageter MH, Menot ML, Wattel E, Fenaux P, Chomienne C. Chronic myelomonocytic leukemia: From biology to therapy. Hematol Cell Ther 1997;39:41-8.
39. List AF, Holmes H, Greenberg PL, Bennett JM, Oster W. Phase II study of amifostine in patients with myelodysplastic syndromes (MDS). Blood 1999;94: 305.abstract.
40. Bowen DT, Denzlinger C, Brugger W, Culligan D, Gelly K, Adlakha S, Groves M, Hepburn M, Kanz L. Poor response rate to continuous schedule of amifostine therapy for "low/intermediate risk" myelodysplastic patients. Br J Haematol 1998;103:785-7.
41. Raza A, Qawi H, Lisak L. Andric T, Dar S, Andrews C, Venugopal P, Gezer S, Gregory S, Loew J, Robin E, Rifkin S, Hsu WT, Huang RW. Patients with myelodysplastic syndromes benefit from palliative therapy with amifosfine, pentoxifylline. and ciprofloxacin with or without dexamethasone. Blood 2000;95:1580-7.
42. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, Buffa R, LambertenghiDeliliers G, Pezzella F. Angiogenesis in myelocysplastic syndromes. Br J Cancer 1999;81:1398-401.
43. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, Du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-65.
44. Sutton L, Leblond V, Le Maignan C. Jouet IP, Kneutz M, Gluckman E, Blaise D, Mark G, Ahal M, Troussard X. Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: Outcome of 86 patients. Bone Marrow Transplant. 1991;7:Suppl. 2:39.abstract.
45. O'Donnell MR, Nademanee AP, Snyds DS, Schmidt GM, Parker PM, Bierman PJ, Fahey IL, Stein AS, Krance RA, Stock AD. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987;5:1822-6.
46. Longmore G, Guinan EC, Weinstein HJ, Gelber RD, Rappeport JM, Antin JH, Tonde marrow transplantation for myelodysplasia and secondary acute non-lymphoblastic leukemia. J Clin Oncol 1990;8: 1707-14.
47. Nevill TJ, Shepherd JD, Reece DE, Barnett MJ, Nantel SH, Klingemann HG, Phillips GL. Treatment of myelodysplastic syndrome with busulfancyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant. 1992; 10:445-50.
48. Ratanatharathom V, Karanes C, Uberti J, Lum LG, dePlanque MM, Schultz KR, Cronin S, Dam ME, Mohamed A, Hussein M. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 1993; 81:2194-9.
49. Anderson JE, Appelbaum FR, Storb R. An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymphoma 1995;17:95-9.